Novartis : Kisqali Increases Survival In Advanced Breast Cancer Patients

(RTTNews) - Novartis (NVS) said that Kisqali delivered consistently superior overall survival. The MONALEESA-3 trial on Kisqali demonstrated more life for postmenopausal HR+/HER2- advanced breast cancer patients.

In MONALEESA-3 trial, Kisqali plus fulvestrant achieved statistically significant overall survival benefit compared to fulvestrant alone in postmenopausal women.

MONALEESA-3 trial evaluated efficacy and safety of Kisqali plus fulvestrant in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative or HR+/HER2- advanced or metastatic breast cancer.

Kisqali is the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials -- consistently demonstrating about 30% reduction in the risk of death, the company said in a statement.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More